Ludwig San Diego
AT EVERY STEP OF THE RESEARCH PROCESS FROM THE LAB TO THE CLINIC, WE ARE PURSUING INNOVATIVE WAYS TO PREVENT AND CONTROL CANCER.
Their findings suggest a novel target for cancer therapy and have significant implications for how oncologists and researchers developing immunotherapies assess T cells found in tumors.
Ludwig researchers have designed a test for circulating tumor DNA to determine a patient’s risk of colon cancer recurrence and monitor the effects of chemotherapy after surgery. The study suggests their liquid biopsy could help improve treatment and outcomes for stage II cancer patients.
Stephen Hodi, an investigator at Ludwig Harvard, reports that 34 percent of patients with advanced melanoma who were treated the immunotherapy nivolumab alone were still alive five years later.